Coronavirus (COVID-19) Update - We are reopening slowly while keeping your safety in mind.
Click here to learn more.
Patients who are diagnosed with RCC will be randomized to the study drug Nivolumab or Observation prior to their scheduled nephrectomy. If randomized to Nivolumab, patients will receive 1 dose prior to surgery and 6 doses after. Patients randomized to observation will proceed straight to surgery and will be monitored by observation afterward.
Jianqing Lin, M.D./Medicine; Division of Hematology/Oncology